Clinical predictors of BRCA1/2 P/LP variants for high-risk breast cancer patients in China: HBRCA-risk prediction - Takeaways - MDSpire

Clinical predictors of BRCA1/2 P/LP variants for high-risk breast cancer patients in China: HBRCA-risk prediction

  • By

  • Wei Gu

  • Chengyin Xu

  • Jinzhen Fu

  • Huijun Lei

  • Najeeb Ullah Khan

  • Ruijiao Lei

  • Xukai Chen

  • Xiao-jia Wang

  • Tianhui Chen

  • June 2, 2026

  • 0 min

Share

  • 1

    The study identified BRCA1/2 pathogenic variants in 8.5% of high-risk breast cancer patients in China, emphasizing the need for genetic testing.

  • 2

    Triple-negative breast cancer and invasive ductal carcinoma were strongly associated with BRCA1/2 variants, while older age reduced risk.

  • 3

    A logistic regression model was developed to predict BRCA1/2 carrier status using clinical data, achieving an AUC of 0.758.

  • 4

    The model demonstrated good calibration and robustness, supporting its clinical utility for guiding genetic testing decisions.

  • 5

    This research highlights the importance of locally adapted models for improving genetic testing access in high-risk breast cancer populations.

Original Source(s)

Clinical predictors of BRCA1/2 P/LP variants for high-risk breast cancer patients in China: HBRCA-risk prediction

  • by Wei Gu, Chengyin Xu, Jinzhen Fu, Huijun Lei, Najeeb Ullah Khan, Ruijiao Lei, Xukai Chen, Xiao-jia Wang, Tianhui Chen

  • June 2, 2026

Related Content

Auricular acupuncture for insomnia in female patients with non-metastatic breast cancer: study protocol for a multicenter, randomized, controlled clinical trial

Neoadjuvant FinHer regimen in patients with HER2-positive breast cancer: a retrospective audit

Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial